split-banner-image

PATINA

Closed

ANZ 1701/AFT-38: PATINA

BCT Study Chair:

Elgene Lim

Patina is an international clinical trial which will enrol 496 patients. It is open to both women and men diagnosed with hormone receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer. The PATINA clinical trial will investigate if the addition of palbociclib to first-line treatment of HER2 positive breast cancer will delay the onset of therapeutic resistance and prolong survival.

international

469

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

49

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

10

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

PATINA PUBLICATIONS

2026

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzalez Farre S, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, oi S, Prat A, Goetz M, Escriva-de-Romani S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Martlett C, Hoynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA. New England Journal of Medicine 2026; 394451-462, DOI: 10.1056/NEJMoa2511218, E-pub

2024

AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER2-Positive Metastatic Breast Cancer.

Metzger O, Mandrekar S, DeMichele A, Gianni L, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzalez Farre X, Francis P, Lynce F, Lanzillotti J, DuFrane C, Drop I, Vaz-Luis I, Valagussa P, Tripathy D, Soi S, Prat A, Goetz M, Escriva-de-Romani S, Porter D, Spoenlein J, Saresai S, Heudel P, Koehler M, Huang Bartlett C, Hoynskyj A, Copalakrishna P, Gauthier E, Liu Y, Slaloge S, Miller K, Winer E, Partridge A, Goel S, Carey L. SABCS 2024; Abstract

2018

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC).

Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer EP, Huang C, Carey L, Francis P, Miller K, Goetz MP, Prat A, Loi S, Krop I, Gianni L, Delalogue S, Vaz-Luis I, Dockter T, Lanzillotti J, Ciruelos E, DeMichele AM. SABCS 2018; OT3-02-07, Poster

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib 1 Anti-HER2 therapy 1 endocrine therapy (ET) vs. anti-HER2 therapy 1 ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC).

Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer EP, Huang C, Cary L, Francis P, Miller KD, Goetz MP, Prat A, Loi S, KropI, Gianni L, Ciruelos EM. Annals of Oncology. 2018; 29(suppl 8):369TiP, Poster

2017

PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + antiHER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer.

Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. SABCS 2017; OT3-05-07, Poster

PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib 1 anti HER2 therapy 1 endocrine therapy vs anti HER2 therapy 1 endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer.

Metzger O, Mandrekar S, Ciruelos E, Loibl S, Valagussa P, Bemichele AM, Lim E, Tripathy D, Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz MP, Prat A, Loi S, Krop I, Gianni L. Annals of Oncology 2017; 28(supp 5):[324TiP], Poster

Institutions